Transforming Traumatic Injuries
Mechanical Tissue Resuscitation (MTR®) is a novel, first-of-its-kind device that uses controlled sub-atmospheric pressure to actively remove excess fluid from injured tissue and reduce secondary damage.
By addressing the swelling, pressure, and tissue stress that follow trauma, it has the potential to fundamentally change how traumatic injuries are treated in the brain, heart, and spine.
Developed by Drs. Louis Argenta and Michael Morykwas at Wake Forest University, MTR® builds on the same negative pressure science behind V.A.C. therapy, but applies it in a new way to internal tissue injury. Its first clinical focus is traumatic brain injury, where it is intended to improve microcirculation, limit swelling, and reduce secondary neuronal damage. Early studies suggest promise across traumatic, ischemic, and hemorrhagic injuries, supporting its potential as a new treatment platform for complex trauma.
Mechanical Tissue Resuscitation ®
-
Addressing the Clinical Problem
MTR® is the controlled application of sub-atmospheric pressure in the treatment of traumatic injuries. For the first indication, TBI, this therapy is a radically new approach in a market that has seen minimal innovation in over a hundred years.
-
Reducing Costs
Effective treatment with MTR® may improve clinical outcomes while significantly reducing hospital stays, creating meaningful cost savings for healthcare systems.
-
Expanding the Market
TBI represents a large, rapidly growing market, driven by the increasing incidence of traumatic brain injuries and growing recognition of their long-term impact on patients and families.